Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Addex Therapeutics ( (CH:ADXN) ) just unveiled an announcement.
Addex Therapeutics announced that preclinical data from its GABAB positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference. The presentation will highlight the antitussive efficacy and therapeutic potential of their lead drug candidate, which is ready for IND enabling studies. This development could position Addex as a significant player in the treatment of chronic cough, offering a potentially more effective and safer alternative to existing treatments like baclofen, which is limited by side effects and reduced efficacy over time.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel small molecule allosteric modulators for neurological disorders. The company’s lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, while a GABAB PAM drug candidate is being developed for substance use disorders in collaboration with Indivior. Addex is also independently advancing a GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which develops allosteric modulator programs for various disorders.
Average Trading Volume: 123,667
Current Market Cap: CHF10.73M
Learn more about ADXN stock on TipRanks’ Stock Analysis page.